nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—GRIN1—telencephalic ventricle—malignant glioma	0.0288	0.0745	CbGeAlD
Amantadine—GRIN2B—telencephalic ventricle—malignant glioma	0.0274	0.071	CbGeAlD
Amantadine—DDC—telencephalic ventricle—malignant glioma	0.0224	0.058	CbGeAlD
Amantadine—DDC—pineal body—malignant glioma	0.0194	0.0503	CbGeAlD
Amantadine—Paranoid reaction—Carmustine—malignant glioma	0.0107	0.0407	CcSEcCtD
Amantadine—DRD2—telencephalic ventricle—malignant glioma	0.00972	0.0252	CbGeAlD
Amantadine—GRIN2C—brainstem—malignant glioma	0.00939	0.0243	CbGeAlD
Amantadine—GRIN2D—brainstem—malignant glioma	0.00873	0.0226	CbGeAlD
Amantadine—GRIN2C—telencephalon—malignant glioma	0.00833	0.0216	CbGeAlD
Amantadine—GRIN1—brainstem—malignant glioma	0.00778	0.0201	CbGeAlD
Amantadine—GRIN2D—telencephalon—malignant glioma	0.00775	0.0201	CbGeAlD
Amantadine—Cerebration impaired—Temozolomide—malignant glioma	0.00746	0.0284	CcSEcCtD
Amantadine—GRIN2B—brainstem—malignant glioma	0.00742	0.0192	CbGeAlD
Amantadine—Visual acuity reduced—Temozolomide—malignant glioma	0.00737	0.0281	CcSEcCtD
Amantadine—GRIN3A—telencephalon—malignant glioma	0.00728	0.0189	CbGeAlD
Amantadine—GRIN1—telencephalon—malignant glioma	0.0069	0.0179	CbGeAlD
Amantadine—Hypokinesia—Carmustine—malignant glioma	0.00672	0.0256	CcSEcCtD
Amantadine—Paranoia—Carmustine—malignant glioma	0.00666	0.0254	CcSEcCtD
Amantadine—DDC—embryo—malignant glioma	0.00661	0.0171	CbGeAlD
Amantadine—GRIN2B—telencephalon—malignant glioma	0.00659	0.0171	CbGeAlD
Amantadine—GRIN2C—medulla oblongata—malignant glioma	0.00655	0.017	CbGeAlD
Amantadine—GRIN2A—brainstem—malignant glioma	0.00649	0.0168	CbGeAlD
Amantadine—GRIN2D—medulla oblongata—malignant glioma	0.00609	0.0158	CbGeAlD
Amantadine—Stupor—Carmustine—malignant glioma	0.00608	0.0232	CcSEcCtD
Amantadine—DDC—brainstem—malignant glioma	0.00606	0.0157	CbGeAlD
Amantadine—GRIN2A—telencephalon—malignant glioma	0.00576	0.0149	CbGeAlD
Amantadine—GRIN2D—spinal cord—malignant glioma	0.00543	0.0141	CbGeAlD
Amantadine—DDC—telencephalon—malignant glioma	0.00538	0.0139	CbGeAlD
Amantadine—Disturbance in attention—Temozolomide—malignant glioma	0.00506	0.0193	CcSEcCtD
Amantadine—GRIN1—midbrain—malignant glioma	0.00496	0.0128	CbGeAlD
Amantadine—GRIN1—spinal cord—malignant glioma	0.00484	0.0125	CbGeAlD
Amantadine—Leukocytosis—Carmustine—malignant glioma	0.00483	0.0184	CcSEcCtD
Amantadine—GRIN2C—central nervous system—malignant glioma	0.00474	0.0123	CbGeAlD
Amantadine—Gait disturbance—Carmustine—malignant glioma	0.00465	0.0177	CcSEcCtD
Amantadine—GRIN2C—cerebellum—malignant glioma	0.00463	0.012	CbGeAlD
Amantadine—GRIN2B—spinal cord—malignant glioma	0.00461	0.012	CbGeAlD
Amantadine—GRIN2A—medulla oblongata—malignant glioma	0.00452	0.0117	CbGeAlD
Amantadine—Gait disturbance—Temozolomide—malignant glioma	0.00449	0.0171	CcSEcCtD
Amantadine—GRIN2D—central nervous system—malignant glioma	0.0044	0.0114	CbGeAlD
Amantadine—Urinary incontinence—Carmustine—malignant glioma	0.00438	0.0167	CcSEcCtD
Amantadine—Depressed level of consciousness—Carmustine—malignant glioma	0.00438	0.0167	CcSEcCtD
Amantadine—GRIN2D—cerebellum—malignant glioma	0.0043	0.0111	CbGeAlD
Amantadine—Depressed level of consciousness—Temozolomide—malignant glioma	0.00423	0.0161	CcSEcCtD
Amantadine—Urinary incontinence—Temozolomide—malignant glioma	0.00423	0.0161	CcSEcCtD
Amantadine—Coma—Carmustine—malignant glioma	0.00415	0.0158	CcSEcCtD
Amantadine—GRIN3A—central nervous system—malignant glioma	0.00414	0.0107	CbGeAlD
Amantadine—GRIN2A—midbrain—malignant glioma	0.00413	0.0107	CbGeAlD
Amantadine—GRIN2A—spinal cord—malignant glioma	0.00403	0.0104	CbGeAlD
Amantadine—Mental disability—Carmustine—malignant glioma	0.00394	0.015	CcSEcCtD
Amantadine—GRIN1—central nervous system—malignant glioma	0.00392	0.0102	CbGeAlD
Amantadine—DDC—midbrain—malignant glioma	0.00386	0.01	CbGeAlD
Amantadine—GRIN1—cerebellum—malignant glioma	0.00384	0.00993	CbGeAlD
Amantadine—Mental disability—Temozolomide—malignant glioma	0.00381	0.0145	CcSEcCtD
Amantadine—GRIN2C—brain—malignant glioma	0.00376	0.00974	CbGeAlD
Amantadine—GRIN2B—central nervous system—malignant glioma	0.00374	0.0097	CbGeAlD
Amantadine—GRIN2B—cerebellum—malignant glioma	0.00366	0.00948	CbGeAlD
Amantadine—Amnesia—Carmustine—malignant glioma	0.00351	0.0134	CcSEcCtD
Amantadine—GRIN2D—brain—malignant glioma	0.0035	0.00905	CbGeAlD
Amantadine—MAOB—embryo—malignant glioma	0.0034	0.00881	CbGeAlD
Amantadine—Amnesia—Temozolomide—malignant glioma	0.00339	0.0129	CcSEcCtD
Amantadine—GRIN3A—brain—malignant glioma	0.00329	0.00851	CbGeAlD
Amantadine—GRIN2A—central nervous system—malignant glioma	0.00327	0.00847	CbGeAlD
Amantadine—GRIN2A—cerebellum—malignant glioma	0.0032	0.00828	CbGeAlD
Amantadine—SLC22A1—telencephalon—malignant glioma	0.00313	0.0081	CbGeAlD
Amantadine—MAOB—brainstem—malignant glioma	0.00312	0.00808	CbGeAlD
Amantadine—GRIN1—brain—malignant glioma	0.00312	0.00807	CbGeAlD
Amantadine—Ataxia—Carmustine—malignant glioma	0.0031	0.0118	CcSEcCtD
Amantadine—DDC—central nervous system—malignant glioma	0.00306	0.00792	CbGeAlD
Amantadine—Liver function test abnormal—Carmustine—malignant glioma	0.00304	0.0116	CcSEcCtD
Amantadine—Ataxia—Temozolomide—malignant glioma	0.00299	0.0114	CcSEcCtD
Amantadine—GRIN2B—brain—malignant glioma	0.00297	0.0077	CbGeAlD
Amantadine—SIGMAR1—telencephalon—malignant glioma	0.00289	0.00749	CbGeAlD
Amantadine—Dysphagia—Carmustine—malignant glioma	0.00285	0.0109	CcSEcCtD
Amantadine—MAOB—telencephalon—malignant glioma	0.00277	0.00717	CbGeAlD
Amantadine—Dysphagia—Temozolomide—malignant glioma	0.00275	0.0105	CcSEcCtD
Amantadine—Sweating increased—Temozolomide—malignant glioma	0.00268	0.0102	CcSEcCtD
Amantadine—Neutropenia—Carmustine—malignant glioma	0.00266	0.0102	CcSEcCtD
Amantadine—DRD2—brainstem—malignant glioma	0.00263	0.00681	CbGeAlD
Amantadine—GRIN2A—brain—malignant glioma	0.0026	0.00673	CbGeAlD
Amantadine—Neutropenia—Temozolomide—malignant glioma	0.00257	0.00981	CcSEcCtD
Amantadine—DRD2—retina—malignant glioma	0.00254	0.00657	CbGeAlD
Amantadine—Photosensitivity reaction—Temozolomide—malignant glioma	0.00251	0.00958	CcSEcCtD
Amantadine—DDC—brain—malignant glioma	0.00243	0.00629	CbGeAlD
Amantadine—DRD2—telencephalon—malignant glioma	0.00234	0.00605	CbGeAlD
Amantadine—SIGMAR1—medulla oblongata—malignant glioma	0.00227	0.00588	CbGeAlD
Amantadine—Hallucination—Carmustine—malignant glioma	0.00227	0.00865	CcSEcCtD
Amantadine—Oedema peripheral—Carmustine—malignant glioma	0.00224	0.00856	CcSEcCtD
Amantadine—Visual impairment—Carmustine—malignant glioma	0.0022	0.00837	CcSEcCtD
Amantadine—Hallucination—Temozolomide—malignant glioma	0.00219	0.00836	CcSEcCtD
Amantadine—Urinary tract disorder—Temozolomide—malignant glioma	0.00217	0.00829	CcSEcCtD
Amantadine—MAOB—medulla oblongata—malignant glioma	0.00217	0.00563	CbGeAlD
Amantadine—Oedema peripheral—Temozolomide—malignant glioma	0.00217	0.00827	CcSEcCtD
Amantadine—Urethral disorder—Temozolomide—malignant glioma	0.00216	0.00823	CcSEcCtD
Amantadine—Eye disorder—Carmustine—malignant glioma	0.00213	0.00812	CcSEcCtD
Amantadine—Visual impairment—Temozolomide—malignant glioma	0.00212	0.00809	CcSEcCtD
Amantadine—ABCB1—blood vessel—malignant glioma	0.00208	0.00539	CbGeAlD
Amantadine—SIGMAR1—midbrain—malignant glioma	0.00208	0.00538	CbGeAlD
Amantadine—Eye disorder—Temozolomide—malignant glioma	0.00206	0.00785	CcSEcCtD
Amantadine—Cardiac disorder—Temozolomide—malignant glioma	0.00204	0.00779	CcSEcCtD
Amantadine—Arrhythmia—Carmustine—malignant glioma	0.00204	0.00776	CcSEcCtD
Amantadine—SIGMAR1—spinal cord—malignant glioma	0.00203	0.00525	CbGeAlD
Amantadine—Alopecia—Carmustine—malignant glioma	0.00201	0.00768	CcSEcCtD
Amantadine—Angiopathy—Temozolomide—malignant glioma	0.002	0.00762	CcSEcCtD
Amantadine—Mental disorder—Carmustine—malignant glioma	0.002	0.00761	CcSEcCtD
Amantadine—MAOB—midbrain—malignant glioma	0.00199	0.00515	CbGeAlD
Amantadine—Mediastinal disorder—Temozolomide—malignant glioma	0.00198	0.00757	CcSEcCtD
Amantadine—Malnutrition—Carmustine—malignant glioma	0.00198	0.00756	CcSEcCtD
Amantadine—Alopecia—Temozolomide—malignant glioma	0.00195	0.00742	CcSEcCtD
Amantadine—MAOB—spinal cord—malignant glioma	0.00194	0.00502	CbGeAlD
Amantadine—Mental disorder—Temozolomide—malignant glioma	0.00193	0.00736	CcSEcCtD
Amantadine—Malnutrition—Temozolomide—malignant glioma	0.00192	0.00731	CcSEcCtD
Amantadine—Vision blurred—Carmustine—malignant glioma	0.00187	0.00713	CcSEcCtD
Amantadine—Tremor—Carmustine—malignant glioma	0.00186	0.00709	CcSEcCtD
Amantadine—Agitation—Carmustine—malignant glioma	0.00182	0.00695	CcSEcCtD
Amantadine—Vision blurred—Temozolomide—malignant glioma	0.00181	0.00689	CcSEcCtD
Amantadine—Tremor—Temozolomide—malignant glioma	0.0018	0.00685	CcSEcCtD
Amantadine—SLC22A1—central nervous system—malignant glioma	0.00178	0.00461	CbGeAlD
Amantadine—Leukopenia—Carmustine—malignant glioma	0.00178	0.00677	CcSEcCtD
Amantadine—Agitation—Temozolomide—malignant glioma	0.00176	0.00672	CcSEcCtD
Amantadine—Convulsion—Carmustine—malignant glioma	0.00172	0.00655	CcSEcCtD
Amantadine—Leukopenia—Temozolomide—malignant glioma	0.00172	0.00654	CcSEcCtD
Amantadine—Hypertension—Carmustine—malignant glioma	0.00171	0.00653	CcSEcCtD
Amantadine—Palpitations—Temozolomide—malignant glioma	0.00169	0.00646	CcSEcCtD
Amantadine—Anxiety—Carmustine—malignant glioma	0.00168	0.00642	CcSEcCtD
Amantadine—DRD2—midbrain—malignant glioma	0.00168	0.00434	CbGeAlD
Amantadine—Convulsion—Temozolomide—malignant glioma	0.00166	0.00633	CcSEcCtD
Amantadine—Hypertension—Temozolomide—malignant glioma	0.00165	0.00631	CcSEcCtD
Amantadine—Confusional state—Carmustine—malignant glioma	0.00163	0.00623	CcSEcCtD
Amantadine—Anxiety—Temozolomide—malignant glioma	0.00163	0.0062	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00162	0.00618	CcSEcCtD
Amantadine—Oedema—Carmustine—malignant glioma	0.00162	0.00617	CcSEcCtD
Amantadine—SIGMAR1—cerebellum—malignant glioma	0.00161	0.00416	CbGeAlD
Amantadine—Dry mouth—Temozolomide—malignant glioma	0.0016	0.00609	CcSEcCtD
Amantadine—Tachycardia—Carmustine—malignant glioma	0.00158	0.00603	CcSEcCtD
Amantadine—Confusional state—Temozolomide—malignant glioma	0.00158	0.00602	CcSEcCtD
Amantadine—MAOB—central nervous system—malignant glioma	0.00157	0.00407	CbGeAlD
Amantadine—Anaphylactic shock—Temozolomide—malignant glioma	0.00156	0.00597	CcSEcCtD
Amantadine—Oedema—Temozolomide—malignant glioma	0.00156	0.00597	CcSEcCtD
Amantadine—Anorexia—Carmustine—malignant glioma	0.00154	0.00589	CcSEcCtD
Amantadine—MAOB—cerebellum—malignant glioma	0.00154	0.00398	CbGeAlD
Amantadine—Nervous system disorder—Temozolomide—malignant glioma	0.00153	0.00585	CcSEcCtD
Amantadine—Skin disorder—Temozolomide—malignant glioma	0.00152	0.0058	CcSEcCtD
Amantadine—Hypotension—Carmustine—malignant glioma	0.00151	0.00577	CcSEcCtD
Amantadine—Hyperhidrosis—Temozolomide—malignant glioma	0.00151	0.00577	CcSEcCtD
Amantadine—Anorexia—Temozolomide—malignant glioma	0.00149	0.00569	CcSEcCtD
Amantadine—Insomnia—Carmustine—malignant glioma	0.00146	0.00558	CcSEcCtD
Amantadine—Paraesthesia—Carmustine—malignant glioma	0.00145	0.00554	CcSEcCtD
Amantadine—Dyspnoea—Carmustine—malignant glioma	0.00144	0.0055	CcSEcCtD
Amantadine—Somnolence—Carmustine—malignant glioma	0.00144	0.00549	CcSEcCtD
Amantadine—Insomnia—Temozolomide—malignant glioma	0.00141	0.0054	CcSEcCtD
Amantadine—SLC22A1—brain—malignant glioma	0.00141	0.00366	CbGeAlD
Amantadine—Decreased appetite—Carmustine—malignant glioma	0.00141	0.00537	CcSEcCtD
Amantadine—Paraesthesia—Temozolomide—malignant glioma	0.0014	0.00536	CcSEcCtD
Amantadine—Gastrointestinal disorder—Carmustine—malignant glioma	0.0014	0.00533	CcSEcCtD
Amantadine—Dyspnoea—Temozolomide—malignant glioma	0.00139	0.00532	CcSEcCtD
Amantadine—Somnolence—Temozolomide—malignant glioma	0.00139	0.0053	CcSEcCtD
Amantadine—Constipation—Carmustine—malignant glioma	0.00138	0.00528	CcSEcCtD
Amantadine—Dyspepsia—Temozolomide—malignant glioma	0.00138	0.00525	CcSEcCtD
Amantadine—Decreased appetite—Temozolomide—malignant glioma	0.00136	0.00519	CcSEcCtD
Amantadine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00135	0.00515	CcSEcCtD
Amantadine—Fatigue—Temozolomide—malignant glioma	0.00135	0.00514	CcSEcCtD
Amantadine—Constipation—Temozolomide—malignant glioma	0.00134	0.0051	CcSEcCtD
Amantadine—Feeling abnormal—Carmustine—malignant glioma	0.00133	0.00509	CcSEcCtD
Amantadine—DRD2—central nervous system—malignant glioma	0.00133	0.00344	CbGeAlD
Amantadine—SIGMAR1—brain—malignant glioma	0.0013	0.00338	CbGeAlD
Amantadine—DRD2—cerebellum—malignant glioma	0.0013	0.00336	CbGeAlD
Amantadine—Feeling abnormal—Temozolomide—malignant glioma	0.00129	0.00492	CcSEcCtD
Amantadine—Body temperature increased—Carmustine—malignant glioma	0.00128	0.00488	CcSEcCtD
Amantadine—MAOB—brain—malignant glioma	0.00125	0.00323	CbGeAlD
Amantadine—ABCB1—embryo—malignant glioma	0.00124	0.00321	CbGeAlD
Amantadine—Body temperature increased—Temozolomide—malignant glioma	0.00124	0.00472	CcSEcCtD
Amantadine—Hypersensitivity—Carmustine—malignant glioma	0.00119	0.00455	CcSEcCtD
Amantadine—Asthenia—Carmustine—malignant glioma	0.00116	0.00443	CcSEcCtD
Amantadine—Hypersensitivity—Temozolomide—malignant glioma	0.00115	0.0044	CcSEcCtD
Amantadine—Asthenia—Temozolomide—malignant glioma	0.00112	0.00428	CcSEcCtD
Amantadine—Diarrhoea—Carmustine—malignant glioma	0.00111	0.00422	CcSEcCtD
Amantadine—Pruritus—Temozolomide—malignant glioma	0.00111	0.00422	CcSEcCtD
Amantadine—ABCB1—retina—malignant glioma	0.0011	0.00284	CbGeAlD
Amantadine—Dizziness—Carmustine—malignant glioma	0.00107	0.00408	CcSEcCtD
Amantadine—Diarrhoea—Temozolomide—malignant glioma	0.00107	0.00408	CcSEcCtD
Amantadine—DRD2—brain—malignant glioma	0.00105	0.00273	CbGeAlD
Amantadine—Dizziness—Temozolomide—malignant glioma	0.00103	0.00395	CcSEcCtD
Amantadine—Vomiting—Carmustine—malignant glioma	0.00103	0.00393	CcSEcCtD
Amantadine—Rash—Carmustine—malignant glioma	0.00102	0.00389	CcSEcCtD
Amantadine—Dermatitis—Carmustine—malignant glioma	0.00102	0.00389	CcSEcCtD
Amantadine—Headache—Carmustine—malignant glioma	0.00101	0.00387	CcSEcCtD
Amantadine—ABCB1—telencephalon—malignant glioma	0.00101	0.00261	CbGeAlD
Amantadine—Vomiting—Temozolomide—malignant glioma	0.000995	0.00379	CcSEcCtD
Amantadine—Rash—Temozolomide—malignant glioma	0.000986	0.00376	CcSEcCtD
Amantadine—Dermatitis—Temozolomide—malignant glioma	0.000986	0.00376	CcSEcCtD
Amantadine—Headache—Temozolomide—malignant glioma	0.00098	0.00374	CcSEcCtD
Amantadine—Nausea—Carmustine—malignant glioma	0.000962	0.00367	CcSEcCtD
Amantadine—Nausea—Temozolomide—malignant glioma	0.000929	0.00354	CcSEcCtD
Amantadine—ABCB1—medulla oblongata—malignant glioma	0.000793	0.00205	CbGeAlD
Amantadine—ABCB1—midbrain—malignant glioma	0.000725	0.00188	CbGeAlD
Amantadine—ABCB1—spinal cord—malignant glioma	0.000707	0.00183	CbGeAlD
Amantadine—ABCB1—central nervous system—malignant glioma	0.000574	0.00149	CbGeAlD
Amantadine—ABCB1—cerebellum—malignant glioma	0.000561	0.00145	CbGeAlD
Amantadine—ABCB1—brain—malignant glioma	0.000455	0.00118	CbGeAlD
Amantadine—GRIN1—Axon guidance—EGFR—malignant glioma	0.000117	0.000334	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000117	0.000332	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CCR4—malignant glioma	0.000116	0.000329	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—VEGFA—malignant glioma	0.000115	0.000326	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—malignant glioma	0.000115	0.000326	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—BRAF—malignant glioma	0.000112	0.000319	CbGpPWpGaD
Amantadine—MAOB—Metabolism—BCHE—malignant glioma	0.000112	0.000318	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000111	0.000316	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—malignant glioma	0.000111	0.000316	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SLC5A5—malignant glioma	0.00011	0.000314	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	0.000109	0.00031	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—malignant glioma	0.000108	0.000308	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.000108	0.000306	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTP1—malignant glioma	0.000106	0.000301	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCR4—malignant glioma	0.000105	0.000299	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP9—malignant glioma	0.000104	0.000295	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—IDH2—malignant glioma	0.000103	0.000294	CbGpPWpGaD
Amantadine—DDC—Metabolism—CAT—malignant glioma	0.000103	0.000292	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP9—malignant glioma	0.000101	0.000288	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MDM2—malignant glioma	0.000101	0.000286	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—RAF1—malignant glioma	0.0001	0.000285	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TNF—malignant glioma	9.83e-05	0.000279	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	9.77e-05	0.000278	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PTEN—malignant glioma	9.72e-05	0.000276	CbGpPWpGaD
Amantadine—DDC—Metabolism—NCOR1—malignant glioma	9.71e-05	0.000276	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP2B6—malignant glioma	9.71e-05	0.000276	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—IDH2—malignant glioma	9.63e-05	0.000274	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCL8—malignant glioma	9.54e-05	0.000271	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	9.46e-05	0.000269	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MDM2—malignant glioma	9.39e-05	0.000267	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—RAF1—malignant glioma	9.36e-05	0.000266	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	9.35e-05	0.000266	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VEGFA—malignant glioma	9.32e-05	0.000265	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—STAT3—malignant glioma	9.22e-05	0.000262	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VEGFA—malignant glioma	9.08e-05	0.000258	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP2B6—malignant glioma	9.05e-05	0.000257	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—STAT3—malignant glioma	8.99e-05	0.000256	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDK—malignant glioma	8.96e-05	0.000255	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTP1—malignant glioma	8.9e-05	0.000253	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—IDH1—malignant glioma	8.88e-05	0.000253	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—COX8A—malignant glioma	8.76e-05	0.000249	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CAT—malignant glioma	8.66e-05	0.000246	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCR3—malignant glioma	8.61e-05	0.000245	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SPHK1—malignant glioma	8.59e-05	0.000244	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DTX1—malignant glioma	8.55e-05	0.000243	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—malignant glioma	8.45e-05	0.00024	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP2C18—malignant glioma	8.42e-05	0.000239	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—malignant glioma	8.38e-05	0.000238	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—IDH1—malignant glioma	8.28e-05	0.000235	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—F2—malignant glioma	8.19e-05	0.000233	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NCOR1—malignant glioma	8.17e-05	0.000232	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—malignant glioma	8.17e-05	0.000232	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SPHK1—malignant glioma	8.01e-05	0.000228	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TNF—malignant glioma	7.98e-05	0.000227	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	7.96e-05	0.000226	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—malignant glioma	7.92e-05	0.000225	CbGpPWpGaD
Amantadine—DDC—Metabolism—CAV1—malignant glioma	7.92e-05	0.000225	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—BDKRB2—malignant glioma	7.87e-05	0.000224	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP2C18—malignant glioma	7.85e-05	0.000223	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCR3—malignant glioma	7.82e-05	0.000222	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TNF—malignant glioma	7.78e-05	0.000221	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—malignant glioma	7.72e-05	0.00022	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	7.58e-05	0.000216	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	7.56e-05	0.000215	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	7.45e-05	0.000212	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ASMT—malignant glioma	7.45e-05	0.000212	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TFRC—malignant glioma	7.44e-05	0.000212	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	7.43e-05	0.000211	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	7.35e-05	0.000209	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CG—malignant glioma	7.21e-05	0.000205	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	7.18e-05	0.000204	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—KNG1—malignant glioma	7.16e-05	0.000204	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—BDKRB2—malignant glioma	7.15e-05	0.000203	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BCAN—malignant glioma	7e-05	0.000199	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPARG—malignant glioma	6.96e-05	0.000198	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	6.84e-05	0.000194	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTT1—malignant glioma	6.81e-05	0.000194	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SUFU—malignant glioma	6.79e-05	0.000193	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HEY2—malignant glioma	6.71e-05	0.000191	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	6.67e-05	0.00019	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CAV1—malignant glioma	6.66e-05	0.000189	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—malignant glioma	6.63e-05	0.000189	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GFAP—malignant glioma	6.55e-05	0.000186	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	6.51e-05	0.000185	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KNG1—malignant glioma	6.5e-05	0.000185	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS1—malignant glioma	6.38e-05	0.000181	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTT1—malignant glioma	6.35e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SPHK1—malignant glioma	6.34e-05	0.00018	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CD—malignant glioma	6.34e-05	0.00018	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	6.26e-05	0.000178	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HEY1—malignant glioma	6.21e-05	0.000177	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCR4—malignant glioma	6.21e-05	0.000177	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CG—malignant glioma	6.07e-05	0.000173	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIST1H3B—malignant glioma	6.04e-05	0.000172	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS1—malignant glioma	5.95e-05	0.000169	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—malignant glioma	5.94e-05	0.000169	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—BCHE—malignant glioma	5.93e-05	0.000169	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC5A5—malignant glioma	5.86e-05	0.000167	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARG—malignant glioma	5.86e-05	0.000167	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—malignant glioma	5.79e-05	0.000165	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL8—malignant glioma	5.77e-05	0.000164	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MMP3—malignant glioma	5.76e-05	0.000164	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	5.66e-05	0.000161	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—IDH2—malignant glioma	5.64e-05	0.00016	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—BCHE—malignant glioma	5.53e-05	0.000157	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CB—malignant glioma	5.53e-05	0.000157	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JAG2—malignant glioma	5.51e-05	0.000157	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—malignant glioma	5.47e-05	0.000156	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC5A5—malignant glioma	5.46e-05	0.000155	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—RAF1—malignant glioma	5.4e-05	0.000153	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CD—malignant glioma	5.34e-05	0.000152	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2B6—malignant glioma	5.31e-05	0.000151	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	5.21e-05	0.000148	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	5.09e-05	0.000145	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—RAF1—malignant glioma	5.03e-05	0.000143	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—IDH1—malignant glioma	4.85e-05	0.000138	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	4.85e-05	0.000138	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	4.81e-05	0.000137	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—malignant glioma	4.77e-05	0.000136	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTP1—malignant glioma	4.72e-05	0.000134	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SPHK1—malignant glioma	4.7e-05	0.000134	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—H3F3A—malignant glioma	4.66e-05	0.000133	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CB—malignant glioma	4.65e-05	0.000132	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—F2—malignant glioma	4.63e-05	0.000132	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR3—malignant glioma	4.62e-05	0.000131	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—malignant glioma	4.61e-05	0.000131	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2C18—malignant glioma	4.6e-05	0.000131	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CAT—malignant glioma	4.59e-05	0.000131	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NTRK2—malignant glioma	4.49e-05	0.000128	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—YWHAE—malignant glioma	4.49e-05	0.000128	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FLT1—malignant glioma	4.47e-05	0.000127	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DUSP6—malignant glioma	4.45e-05	0.000127	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CG—malignant glioma	4.43e-05	0.000126	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	4.42e-05	0.000126	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTP1—malignant glioma	4.4e-05	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JAG1—malignant glioma	4.4e-05	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH3—malignant glioma	4.38e-05	0.000124	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NCOR1—malignant glioma	4.34e-05	0.000123	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FBXW7—malignant glioma	4.31e-05	0.000122	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CAT—malignant glioma	4.28e-05	0.000122	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	4.28e-05	0.000122	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BDKRB2—malignant glioma	4.22e-05	0.00012	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—F2—malignant glioma	4.2e-05	0.00012	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT2—malignant glioma	4.05e-05	0.000115	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NCOR1—malignant glioma	4.04e-05	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CG—malignant glioma	4.02e-05	0.000114	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—malignant glioma	4.02e-05	0.000114	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTPN11—malignant glioma	3.95e-05	0.000112	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH2—malignant glioma	3.93e-05	0.000112	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CD—malignant glioma	3.9e-05	0.000111	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KNG1—malignant glioma	3.84e-05	0.000109	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTT1—malignant glioma	3.72e-05	0.000106	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT2—malignant glioma	3.68e-05	0.000105	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NTRK1—malignant glioma	3.66e-05	0.000104	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	3.61e-05	0.000103	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CD—malignant glioma	3.54e-05	0.000101	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CAV1—malignant glioma	3.54e-05	0.000101	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS1—malignant glioma	3.49e-05	9.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP3—malignant glioma	3.4e-05	9.68e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CB—malignant glioma	3.4e-05	9.65e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN2B—malignant glioma	3.37e-05	9.6e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—malignant glioma	3.37e-05	9.58e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CAV1—malignant glioma	3.3e-05	9.37e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTK2—malignant glioma	3.28e-05	9.32e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—malignant glioma	3.26e-05	9.28e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BCHE—malignant glioma	3.24e-05	9.22e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CG—malignant glioma	3.22e-05	9.16e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HES1—malignant glioma	3.22e-05	9.16e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC5A5—malignant glioma	3.2e-05	9.1e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NCOR1—malignant glioma	3.2e-05	9.1e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RAF1—malignant glioma	3.16e-05	8.98e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—malignant glioma	3.12e-05	8.87e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARG—malignant glioma	3.11e-05	8.84e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CB—malignant glioma	3.08e-05	8.77e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRA—malignant glioma	3.07e-05	8.72e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CG—malignant glioma	3e-05	8.54e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SPP1—malignant glioma	2.98e-05	8.46e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—malignant glioma	2.96e-05	8.43e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	2.95e-05	8.38e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARG—malignant glioma	2.9e-05	8.24e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—malignant glioma	2.84e-05	8.06e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CD—malignant glioma	2.83e-05	8.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—malignant glioma	2.83e-05	8.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—malignant glioma	2.82e-05	8.02e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFB—malignant glioma	2.75e-05	7.83e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—malignant glioma	2.75e-05	7.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR1—malignant glioma	2.74e-05	7.79e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIF1A—malignant glioma	2.7e-05	7.67e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CD—malignant glioma	2.64e-05	7.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CAV1—malignant glioma	2.61e-05	7.42e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KDR—malignant glioma	2.58e-05	7.34e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTP1—malignant glioma	2.58e-05	7.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CAT—malignant glioma	2.51e-05	7.14e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—F2—malignant glioma	2.48e-05	7.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FN1—malignant glioma	2.48e-05	7.06e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CB—malignant glioma	2.47e-05	7.02e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BAD—malignant glioma	2.45e-05	6.98e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—malignant glioma	2.45e-05	6.95e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH1—malignant glioma	2.43e-05	6.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD80—malignant glioma	2.38e-05	6.77e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APC—malignant glioma	2.38e-05	6.76e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CG—malignant glioma	2.38e-05	6.76e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOR1—malignant glioma	2.37e-05	6.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGF—malignant glioma	2.35e-05	6.68e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTPN11—malignant glioma	2.34e-05	6.64e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—malignant glioma	2.32e-05	6.59e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CB—malignant glioma	2.3e-05	6.54e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—malignant glioma	2.28e-05	6.48e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—malignant glioma	2.23e-05	6.35e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT2—malignant glioma	2.17e-05	6.18e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—malignant glioma	2.17e-05	6.16e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—malignant glioma	2.13e-05	6.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CD—malignant glioma	2.09e-05	5.94e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—malignant glioma	2.07e-05	5.89e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—malignant glioma	2.05e-05	5.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF2—malignant glioma	2e-05	5.69e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—malignant glioma	1.99e-05	5.65e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CAV1—malignant glioma	1.93e-05	5.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	1.88e-05	5.34e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDM2—malignant glioma	1.87e-05	5.32e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAF1—malignant glioma	1.87e-05	5.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—malignant glioma	1.85e-05	5.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CB—malignant glioma	1.82e-05	5.18e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CG—malignant glioma	1.76e-05	5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—malignant glioma	1.75e-05	4.98e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARG—malignant glioma	1.7e-05	4.83e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—malignant glioma	1.69e-05	4.81e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—malignant glioma	1.68e-05	4.76e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—malignant glioma	1.67e-05	4.76e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—malignant glioma	1.58e-05	4.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—malignant glioma	1.57e-05	4.48e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CD—malignant glioma	1.55e-05	4.4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—malignant glioma	1.54e-05	4.37e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—malignant glioma	1.5e-05	4.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—malignant glioma	1.42e-05	4.04e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—malignant glioma	1.41e-05	4e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—malignant glioma	1.4e-05	3.99e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CB—malignant glioma	1.35e-05	3.83e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—malignant glioma	1.34e-05	3.8e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—malignant glioma	1.31e-05	3.72e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—malignant glioma	1.28e-05	3.64e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—malignant glioma	1.23e-05	3.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—malignant glioma	1.21e-05	3.44e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—malignant glioma	1.17e-05	3.31e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—malignant glioma	1.15e-05	3.26e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—malignant glioma	1.11e-05	3.16e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—malignant glioma	1.07e-05	3.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—malignant glioma	9.07e-06	2.58e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—malignant glioma	8.22e-06	2.34e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—malignant glioma	6.71e-06	1.91e-05	CbGpPWpGaD
